PERSPECTA

News from every angle

Back to headlines

Review Finds New Alzheimer's Drugs Lack Benefit, Pose Risks

A recent comprehensive review has concluded that new Alzheimer's drugs, particularly those targeting amyloid, offer little meaningful benefit to patients and may present more risks than advantages. This finding challenges the efficacy of much-hyped treatments for the neurodegenerative disease.

16 Apr, 00:00 — 16 Apr, 06:56
PostShare

Source Diversity

Source Diversity

Excellent (92/100)
14 sources33/33
Spectrum spread4/5 buckets covered25/33
Far L3
Far Left (3)
aftonbladetNYTThe Guardian
Left4
Left (4)
politikenrte-newsBBCjapan-times
Center1
Center (1)
20-minuten
Right6
Right (6)
irish-independentdie-pressesvenska-dagbladetstraits-timesfazel-mundo
Far R
Geographic diversity11 regions34/34
Ireland2UK2Sweden2Denmark1Austria1Singapore1Japan1Switzerland1Germany1Spain1US1

Sources

Showing 7 of 14 sources
BBCHigh80d ago

Report suggests 'breakthrough' Alzheimer's drugs unlikely to benefit patients

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

Read full article →
NYTMostly Factual80d ago

Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.

By Pam Belluck

Read full article →
The GuardianMostly Factual80d ago

Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes

Data assessed from 17 clinical trials of anti-amyloid drugs found no ‘meaningful effect’ on cognitive decline Drugs that have been hailed as a gamechanger for the treatment of Alzheimer’s disease make no noticeable difference to patients, according to an extensive review. The analysis of clinical trials in people with mild cognitive impairment or mild dementia found that the effects of anti-amyloid drugs on cognition and dementia severity over 18 months were “trivial”, with improvements in fu...

By Ian Sample Science editor

Read full article →
straits-timesMostly Factual80d ago

Much-hyped Alzheimer’s drugs do not help patients, review finds - The Straits Times

Much-hyped Alzheimer’s drugs do not help patients, review finds  The Straits Times

Read full article →
rte-newsMostly Factual80d ago

Alzheimer's drugs make 'no meaningful difference'

Drugs that are said to slow the progression of Alzheimer's disease "make no meaningful difference to patients" while increasing the risk of swelling and bleeding in the brain, according to a new review.

Read full article →
irish-independent80d ago

‘Weight-loss jabs have been hijacked by Hollywood and middle-upper-income people’ – Measuring the effects of GLP-1s on Irish society

Transformative wonder drugs or overhyped sticking plasters on a much deeper problem? GLP-1 drugs Ozempic, Wegovy, Mounjaro and Zepbound are not just so-called ‘weight-loss jabs’, but fascinating barometers of our culture, behaviour and obsession with thinness.

Read full article →
japan-timesMostly Factual80d ago

Alzheimer’s drugs targeting amyloid don’t help, review finds

Despite successfully removing amyloid from the brain, the drugs don't improve cognitive function or slow its decline.

Read full article →